FY2025 · ended Dec 31, 2025 · Revenue $109.43M, +18.8% YoY · Filed Mar 12, 2026
OptimizeRx Corporation (OPRX) files with the SEC under industry code 7389, Services-Business Services, NEC. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $109.4 million and net income of $5.1 million. Free cash flow was $18.7 million. As of Jun 30, 2026 it held $24.1 million in cash and investments and $20.2 million in total debt.
Revenue (TTM)
$98.65M
-5.8% vs year-ago TTM
Net income (TTM)
$4.60M
+146.6% vs year-ago TTM
Operating cash flow (TTM)
$18.43M
+77.0% vs year-ago TTM
Free cash flow (TTM)
$18.36M
EPS (TTM)
$0.24
+144.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
18.76M
+1.5% vs prior year
Net cash
$3.94M
as of Jun 30, 2026
Operating margin
11.0%
FY 2026
Company profile
- Industry
- Services-Business Services, NEC (SIC 7389)
- Listed as
- OPRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1448431
Other Services-Business Services, NEC companies
- Visa Inc. V
- Mastercard Inc MA
- Alibaba Group Holding Ltd BABA
- Accenture plc ACN
- Uber Technologies, Inc UBER
- PDD Holdings Inc. PDD
- Mercadolibre Inc MELI
- DoorDash, Inc. DASH
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $109.4M | $92.1M | $71.5M | $62.5M | $61.3M |
| Operating income | $11.7M | -$13.7M | -$26.4M | -$12.3M | $361,100 |
| Net income | $5.1M | -$20.1M | -$17.6M | -$11.4M | $378,079 |
| Diluted EPS | $0.27 | -$1.10 | -$1.03 | -$0.64 | $0.02 |
| Operating cash flow | $18.7M | $4.9M | -$7.2M | $10.7M | $726,039 |
| Free cash flow | $18.7M | $4.8M | -$7.3M | $10.6M | $625,717 |
| Total assets | $176.9M | $171.2M | $183.4M | $134.7M | $141.0M |
| Total liabilities | $48.6M | $54.2M | $56.8M | $8.5M | $9.6M |
| Stockholders' equity | $128.3M | $117.0M | $126.6M | $126.1M | $131.4M |
| Cash and investments | $23.4M | $13.4M | $13.9M | $74.1M | $84.7M |
| Total debt | $26.7M | $34.7M | $38.9M | $234,434 | $327,708 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Aug 12, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 12, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 1, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Results of operations, New debt
|
May 12, 2026 | May 12, 2026 |
All 1000 OptimizeRx Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.